BASKING RIDGE, N.J., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development and manufacturing services provider with a therapeutic development pipeline, announces today that Company management will present at the BIO CEO & Investor Conference and Source Capital’s Disruptive Growth & Healthcare Conference in February.
18th Annual BIO CEO & Investor Conference
- Venue: The Waldorf Astoria, New York, NY
- Website: http://www.bio.org/events/conferences/bio-ceo-investor-conference
- Date and Time: Tuesday, February 9, 2016, 11:30 AM ET
- Presenter: David Mazzo, Ph.D., Chief Executive Officer, Caladrius Biosciences
- Topic: Company Overview
- Webcast: www.caladrius.com/investors/overview (archived for 90 days)
Source Capital’s 2016 Disruptive Growth & Healthcare Conference
- Venue: Convene, New York, NY
- Website: http://clbs.bio/1n6TlDD
- Date and Time: Wednesday, February 10, 2016, 12:30 PM ET
- Presenter: Joseph Talamo, Senior Vice President and Chief Financial Officer, Caladrius Biosciences
- Topic: Company Overview
- Webcast: www.caladrius.com/investors/overview (archived for 90 days)
About Caladrius Biosciences
Caladrius Biosciences, Inc., through its wholly-owned subsidiary, PCT, is a leading development and manufacturing partner to the cell therapy industry. Caladrius works with its clients to overcome the fundamental challenges presented by cell therapy manufacturing by providing a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support. Around this core expertise, Caladrius strategically develops product candidates, which currently include an innovative therapy for type 1 diabetes based on a proprietary platform technology for immunomodulation, and holds intellectual property around other cell therapy platform technologies. For more information, visit www.caladrius.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding our expected revenues and capital expenditures, personnel reductions, as well as the potential of CLBS03 in the treatment of recent-onset type 1 diabetes and the expected cost savings associated with the termination of the CLBS20 study. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 2, 2015, and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control.